Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Available 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 211Lymphoid 184Myeloid 121Plasma cell 101Classical hematology 46Sarcoma 45Dermatologic 44Genitourinary 29Breast 27Gynecologic 24CNS 23Other solid neoplasm 7Other neoplasm 6Gastrointestinal 4Thoracic 3Head & Neck 3Tumor-Agnostic 2

Conditions

Neoplasms 2

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Peripheral Blood Stem Cell Transplantation × Tumor-Agnostic × Clear all
NCT03626285 2026-01-02

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

OHSU Knight Cancer Institute

Available
Tumor-Agnostic

Neoplasms

NCT01525407 2017-08-17

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Completed
83 enrolled 16 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡